Drug Interactions between tadalafil and Tecvayli
This report displays the potential drug interactions for the following 2 drugs:
- tadalafil
- Tecvayli (teclistamab)
Interactions between your drugs
tadalafil teclistamab
Applies to: tadalafil and Tecvayli (teclistamab)
MONITOR: Coadministration with teclistamab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of teclistamab treatment causes transient release of cytokines that may suppress CYP450 isoenzymes, although the potential for interaction has not been studied. According to the manufacturer, the highest drug-drug interaction risk would be from the start of teclistamab therapy (including the initial step-up dosing schedule) up to 7 days after the first treatment dose (considered to be the first weekly dose administered after the completion of the step-up dosing schedule), as well as during and after cytokine release syndrome.
MANAGEMENT: Caution is advised when teclistamab is coadministered with drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic range, where minimal changes to concentration may lead to significant adverse reactions, such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and/or laboratory monitoring are recommended, particularly at the initial phase of treatment with teclistamab as well as during and after cytokine release syndrome, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.
References (2)
- (2022) "Product Information. Tecvayli (teclistamab)." Janssen Biotech, Inc.
- (2023) "Product Information. Tecvayli (teclistamab)." Janssen-Cilag Pty Ltd, 3.230113
Drug and food/lifestyle interactions
tadalafil food/lifestyle
Applies to: tadalafil
GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of tadalafil, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.
MONITOR: Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors such as tadalafil are used with alcohol, as both are mild systemic vasodilators. In clinical pharmacology studies, more subjects administered alcohol at a dose of 0.7 g/kg (equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male; consumed within 10 minutes in study subjects, providing blood alcohol levels of 0.08%) in combination with tadalafil 10 or 20 mg single doses had clinically significant decreases in blood pressure than with alcohol alone. There were reports of postural dizziness, and orthostatic hypotension was observed in some. When tadalafil 20 mg was administered with alcohol at a lower dose of 0.6 g/kg (equivalent to approximately 4 ounces of 80-proof vodka in an 80-kg male), orthostatic hypotension was not observed, dizziness occurred with similar frequency relative to alcohol alone, and the hypotensive effects of alcohol were not potentiated. Neither tadalafil nor alcohol affected the plasma concentrations of the other.
MANAGEMENT: Caution is recommended with concurrent consumption of large amounts of alcohol in patients taking tadalafil as it may increase the potential for orthostatic signs and symptoms, such as increase in heart rate, decrease in standing blood pressure, dizziness, and headache. It may also be appropriate to avoid consuming large amounts of grapefruit juice.
References (8)
- (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
- (2024) "Product Information. Opsynvi (macitentan-tadalafil)." Actelion Pharmaceuticals US Inc
- (2023) "Product Information. Adcirca (tadalafil)." Eli Lilly and Company Ltd
- (2024) "Product Information. Opsynvi 10/40 (macitentan-tadalafil)." Janssen-Cilag Pty Ltd
- (2025) "Product Information. Opsynvi (macitentan-tadalafil)." Janssen Inc
- (2019) "Product Information. Tadalafil (tadalafil)." Amneal Pharmaceuticals LLC
- (2021) "Product Information. Ach-Tadalafil (tadalafil)." Accord Healthcare Inc
- (2024) "Product Information. Cialis (tadalafil)." Eli Lilly Australia Pty Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.